Thymoma Patients Treated in a Phase I Clinic at MD Anderson Cancer Center: Responses to mTOR Inhibitors and Molecular Analyses-Reference-Cited by-同舟云学术

Thymoma Patients Treated in a Phase I Clinic at MD Anderson Cancer Center: Responses to mTOR Inhibitors and Molecular Analyses

Published:2013-06-10 Issue:6 Volume:4 Page:890-898
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Wheler Jennifer¹,Hong David¹,Swisher Stephen G.²,Falchook Gerald¹,Tsimberidou Apostolia M.¹,Helgason Thorunn¹,Naing Aung¹,Stephen Bettzy¹,Janku Filip¹,Stephens Philip J.³,Yelensky Roman³,Kurzrock Razelle⁴

Affiliation:

1. Department of Investigational Cancer Therapeutics - a Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center

2. Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center

3. Foundation Medicine, University of California, San Diego

4. Moores Cancer Center, University of California, San Diego

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Survival Outcome After Surgery in Patients With Thymoma Distant Recurrence;Journal of Thoracic Oncology;2024-07

2. Immunotherapy and Targeted Therapies Efficacy in Thymic Epithelial Tumors: A Systematic Review;Biomedicines;2023-10-08

3. Unraveling molecular networks in thymic epithelial tumors: deciphering the unique signatures;Frontiers in Immunology;2023-10-02

4. Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations;Nature Cancer;2023-09-21

5. Somatic mutations of thymic epithelial tumors with myasthenia gravis;Frontiers in Oncology;2023-08-21